Source: Reuters (via feed)
India’s market for diabetes and weight-loss drugs is facing change. Danish drugmaker Novo Nordisk’s patent on semaglutide expires this week. This expiry triggers a wave of cheaper generic drugs from local drugmakers. There are also worries about uneven regulatory oversight in this overcrowded market.
BizTrendWire Insight:
Patent expiry allows local manufacturers to produce generic semaglutide. This changes the supply dynamic for diabetes and weight-loss drugs in India.
Patent expiry allows local manufacturers to produce generic semaglutide. This changes the supply dynamic for diabetes and weight-loss drugs in India.
